🟢 Incyte Corporation is trading 4.1% up today as investors cheer the company's largest-ever acquisition

Incyte Corporation is trading 4.1% up at $107.43 as the stock continues to rally following a major strategic move.

• On June 8, 2026, Incyte announced its largest acquisition to date, agreeing to buy Vega Therapeutics for $1.25 billion upfront. [11, 12]
• The deal, with a potential total value of up to $2.0 billion, adds a promising Phase 3 drug for the bleeding disorder von Willebrand disease to its hematology portfolio. [11, 12]
• The acquisition is seen by the company as a key future growth driver, and the market has reacted positively to the news, contributing to the stock's recent price appreciation.